Global Point-of-Care Glucose Testing Market was valued at USD XX Billion in the year 2021. Global Point-of-Care Glucose Testing Market is further estimated to grow at a CAGR of XX% from 2022 to 2030 it will reach USD XX Billion by the year 2030. The North America region holds the highest market share in 2021 and the Asia Pacific is considered as the fastest growing market in the forecasted period. At a country level, US, China are projected to grow strongly in the coming years due to increasing density of population and funding through Research and Development. The Global Point-of-Care Glucose Testing Report 2022-2030 covers market opportunities and challenges, key market regulations’ information, analysis of new products from the market players and key market trends, market share analysis for key players, supply chain and value chain analysis, product and Material trends, pricing analysis, emerging applications, technologies and major recent developments. This information has also been provided for the major country markets in these regions. Market shares, size and growth potential are assessed for these major country markets. Market opportunities, challenges, government regulations, market share analysis by major competitors, recent major market developments (product launches, M&A, partnerships, etc.) and other information have been covered for the major country markets listed in this section. On the basis of Type, the market is divided as Glucose Monitoring, Cardiometabolic Testing, Infectious Disease Testing, Coagulation Testing, Pregnancy and Fertility Testing, Tumor/Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Hematology Testing, Drugs-of-Abuse Testing, Fecal Occult Testing. In which Glucose Monitoring for the largest market share due to increasing demand in future market trends. Regional breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and ROW. Market player analysis of major companies such as Abaxis, Inc., Abbott Laboratories, Accubiotech Co, Ltd., ACON Laboratories, Inc., Becton, Dickinson and Company.

1 INTRODUCTION 1.1 OBJECTIVES 1.2 RESEARCH METHODOLOGY 1.2.1 SECONDARY DATA 1.2.2 PRIMARY DATA 1.2.3 MARKET SIZE ESTIMATION 1.2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 1.3 STAKEHOLDERS 1.4 RESEARCH ASSUMPTIONS 1.5 LIMITATION 2 EXECUTIVE SUMMARY 3 MARKET OUTLOOK 3.1 INTRODUCTION 3.2 OPPORTUNITIES MATRIX 3.3 MARKET CHALLENGES 3.4 MARKET SHARE ANALYSIS 3.5 VALUE CHAIN ANALYSIS 3.6 DEMAND SIDE ANALYSIS 3.7 SUPPLY SIDE ANALYSIS 3.8 PORTER’S FIVE FORCES MODEL 3.8.1 DEGREE OF COMPETITION 3.8.2 BARGAINING POWER OF BUYERS 3.8.3 BARGAINING POWER OF SUPPLIERS 3.8.4 THREAT FROM SUBSTITUTES 3.8.5 THREAT FROM NEW ENTRANTS 4 INDUSTRY TRENDS 4.1 PRODUCT LIFE CYCLE 4.2 NEW MARKET ENTRY STRATEGY 4.3 PESTEL ANALYSIS 4.4 PRICING ANALYSIS 4.5 TRADE DATA 4.6 TECHNOLOGICAL OVERVIEW 4.7 FUTURE OUTLOOK MARKET TRENDS 4.8 MACRO-ECONOMIC VARIABLES (DEPENDENT AND INDEPENDENT VARIABLES) 4.9 MULTIFACTOR BASED SENSITIVITY ANALYSIS 4.10 REGRESSION MATRIX 4.11 COVID-19 IMPACT ANALYSES 4.12 GE MATRIX 5 POINT-OF-CARE GLUCOSE TESTING TYPE ANALYSIS 5.1 INTRODUCTION 5.2 HISTORICAL MARKET TYPE ANALYSIS, 2016-2020 5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 5.4 Y-O-Y GROWTH TREND ANALYSIS 5.5 GLUCOSE MONITORING 5.5.1 STRIPS 5.5.2 METERS 5.5.3 LANCETS 5.6 CARDIOMETABOLIC TESTING 5.6.1 CARDIAC MARKER TESTING 5.6.1.1 hsTnl 5.6.1.2 BNP 5.6.1.3 D-dimer 5.6.1.4 CK-MB 5.6.1.5 Myoglobin 5.6.1.6 Others 5.6.2 BLOOD GAS/ELECTROLYTES TESTING 5.6.3 HBA1C TESTING 5.7 INFECTIOUS DISEASE TESTING 5.7.1 INFLUENZA TESTING 5.7.2 HIV TESTING 5.7.3 HEPATITIS C TESTING 5.7.4 SEXUALLY TRANSMITTED DISEASE (STD) TESTING 5.7.5 HEALTHCARE-ASSOCIATED INFECTION (HAI) TESTING 5.7.6 RESPIRATORY INFECTION TESTING 5.7.7 TROPICAL DISEASE TESTING 5.7.8 OTHER INFECTIOUS DISEASES TESTING 5.8 COAGULATION TESTING 5.8.1 PT/INR TESTING 5.8.2 ACTIVATED CLOTTING TIME (ACT/APTT) TESTING 5.9 PREGNANCY AND FERTILITY TESTING 5.9.1 PREGNANCY TESTING 5.9.2 FERTILITY TESTING 5.10 TUMOR/CANCER MARKER TESTING 5.11 URINALYSIS TESTING 5.12 CHOLESTEROL TESTING 5.13 HEMATOLOGY TESTING 5.14 DRUGS-OF-ABUSE TESTING 5.15 FECAL OCCULT TESTING 5.16 OTHERS 6 POINT-OF-CARE GLUCOSE TESTING PRODUCT ANALYSIS 6.1 INTRODUCTION 6.2 HISTORICAL MARKET PRODUCT ANALYSIS, 2016-2020 6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 6.4 Y-O-Y GROWTH TREND ANALYSIS 6.5 ACCU-CHEK INFORM II 6.6 STATSTRIP 6.7 ONETOUCH VERIO FLEX 6.8 FREESTYLE LITE 6.9 ACCU CHECK AVIVA METER 6.10 TRUE METRIX 6.11 BAYER CONTOUR BLOOD GLUCOSE MONITORING SYSTEM 6.12 I-STAT 7 POINT-OF-CARE GLUCOSE TESTING TECHNOLOGY ANALYSIS 7.1 INTRODUCTION 7.2 HISTORICAL MARKET TECHNOLOGY ANALYSIS, 2016-2020 7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 7.4 Y-O-Y GROWTH TREND ANALYSIS 7.5 LATERAL FLOW ASSAYS 7.6 DIPSTICKS 7.7 MICROFLUIDICS 7.8 MOLECULAR DIAGNOSTICS 7.9 IMMUNOASSAYS 7.10 AGGLUTINATION ASSAYS 7.11 FLOW-THROUGH 7.12 SOLID PHASE 7.13 BIOSENSORS 8 POINT-OF-CARE GLUCOSE TESTING PRESCRIPTION ANALYSIS 8.1 INTRODUCTION 8.2 HISTORICAL MARKET PRESCRIPTION ANALYSIS, 2016-2020 8.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 8.4 Y-O-Y GROWTH TREND ANALYSIS 8.5 OTC TESTING 8.6 PRESCRIPTION-BASED TESTING 9 POINT-OF-CARE GLUCOSE TESTING END USE ANALYSIS 9.1 INTRODUCTION 9.2 HISTORICAL MARKET END USE ANALYSIS, 2016-2020 9.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 9.4 Y-O-Y GROWTH TREND ANALYSIS 9.5 HOSPITALS 9.6 DIAGNOSTIC CENTERS 9.7 RESEARCH LABORATORIES 9.8 HOME-CARE SETTINGS 9.9 OTHERS 10 POINT-OF-CARE GLUCOSE TESTING MARKET APPLICATION ANALYSIS 10.1 INTRODUCTION 10.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2016-2020 10.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 10.4 Y-O-Y GROWTH TREND ANALYSIS 10.5 CARDIO METABOLIC TESTING 10.6 INFECTIOUS DISEASE TESTING 10.7 NEPHROLOGY TESTING 10.8 DRUG-OF-ABUSE (DOA) TESTING 10.9 BLOOD GLUCOSE TESTING 10.10 PREGNANCY TESTING 10.11 CANCER BIOMARKER TESTING 10.12 OTHER APPLICATIONS 11 GLOBAL POINT-OF-CARE GLUCOSE TESTING REGIONAL ANALYSIS 11.1 INTRODUCTION 11.2 NORTH AMERICA 11.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020 11.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 11.2.3 Y-O-Y GROWTH TREND ANALYSIS 11.2.3.1 U.S. 11.2.3.2 Canada 11.2.3.3 Mexico 11.3 ASIA-PACIFIC 11.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020 11.3.2 Y-O-Y GROWTH TREND ANALYSIS 11.3.2.1 China 11.3.2.2 Japan 11.3.2.3 Korea 11.3.2.4 India 11.3.2.5 Southeast Asia 11.4 MIDDLE EAST AND AFRICA 11.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020 11.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 11.4.3 Y-O-Y GROWTH TREND ANALYSIS 11.4.3.1 Saudi Arabia 11.4.3.2 UAE 11.4.3.3 Egypt 11.4.3.4 Nigeria 11.4.3.5 South Africa 11.5 EUROPE 11.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020 11.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 11.5.3 Y-O-Y GROWTH TREND ANALYSIS 11.5.3.1 Germany 11.5.3.2 France 11.5.3.3 UK 11.5.3.4 Russia 11.5.3.5 Italy 11.6 LATIN AMERICA 11.6.1 LATIN AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020 11.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030 11.6.3 Y-O-Y GROWTH TREND ANALYSIS 11.6.3.1 Brazil 11.6.3.2 Argentina 11.6.3.3 Columbia 12 MARKET PLAYERS 12.1 F. HOFFMANN-LA ROCHE LTD. 12.1.1 BUSINESS OVERVIEW: 12.1.2 PRODUCT PORTFOLIO 12.1.3 RECENT DEVELOPMENTS 12.1.4 SWOT ANALYSIS: 12.2 ABBOTT 12.3 NIPRO 12.4 PLATINIUM EQUITY ADVISORS, LLC (LIFESCAN, INC.) 12.5 NOVA BIOMEDICAL 12.6 ACON LABORATORIES 12.7 TRIVIDIA HEALTH, INC. 12.8 PRODIGY DIABETES CARE, LLC 12.9 BAYER AG/ASCENSIA DIABETES CARE HOLDINGS AG 12.10 EKF DIAGNOSTICS 12.11 ABAXIS, INC. 12.12 ACCUBIOTECH CO, LTD. 12.13 BECTON 12.14 DICKINSON AND COMPANY. 13 ABOUT US

TABLE 1 POINT-OF-CARE GLUCOSE TESTING REGIONAL ANALYSIS, 2021–2030 (USD MILLION) TABLE 2 GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET, 2021–2030, (USD MILLION) TABLE 3 POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE REGIONAL ANALYSIS, 2021–2030 (USD MILLION) TABLE 4 GLOBAL POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET TYPE ANALYSIS, 2016-2020, (USD MILLION) TABLE 5 POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION) TABLE 6 GLOBAL POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET PRODUCT ANALYSIS, 2016-2020, (USD MILLION) TABLE 7 POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030 (USD MILLION) TABLE 8 GLOBAL POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET TECHNOLOGY ANALYSIS, 2016-2020, (USD MILLION) TABLE 9 POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030 (USD MILLION) TABLE 10 GLOBAL POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET PRESCRIPTION ANALYSIS, 2016-2020, (USD MILLION) TABLE 11 POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030 (USD MILLION) TABLE 12 GLOBAL POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET END USE ANALYSIS, 2016-2020, (USD MILLION) TABLE 13 POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION) TABLE 14 GLOBAL POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET APPLICATION ANALYSIS, 2016-2020, (USD MILLION) TABLE 15 POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION) TABLE 16 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION) TABLE 17 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION) TABLE 18 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030 (USD MILLION) TABLE 19 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030 (USD MILLION) TABLE 20 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030 (USD MILLION) TABLE 21 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION) TABLE 22 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION) TABLE 23 U.S. POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2016–2021 TABLE 24 U.S. POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 25 U.S. POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 26 CANADA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 27 CANADA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 28 MEXICO POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 29 MEXICO POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 30 APAC POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION) TABLE 31 ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION) TABLE 32 ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030 (USD MILLION) TABLE 33 ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030 (USD MILLION) TABLE 34 ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030 (USD MILLION) TABLE 35 ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION) TABLE 36 ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION) TABLE 37 CHINA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 38 CHINA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 39 JAPAN POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 40 JAPAN POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 41 KOREA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 42 KOREA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 43 INDIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 44 INDIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 45 SOUTHEAST ASIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 46 SOUTHEAST ASIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 47 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION) TABLE 48 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION) TABLE 49 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030 (USD MILLION) TABLE 50 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030 (USD MILLION) TABLE 51 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030 (USD MILLION) TABLE 52 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION) TABLE 53 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION) TABLE 54 SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 55 SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 56 UAE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 57 UAE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 58 EGYPT POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 59 EGYPT POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 60 NIGERIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 61 NIGERIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 62 SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 63 SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 64 EUROPE POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION) TABLE 65 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION) TABLE 66 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030 (USD MILLION) TABLE 67 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030 (USD MILLION) TABLE 68 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030 (USD MILLION) TABLE 69 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION) TABLE 70 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION) TABLE 71 GERMANY POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 72 GERMANY POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 73 FRANCE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 74 FRANCE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 75 UK POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 76 UK POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 77 RUSSIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 78 RUSSIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 79 ITALY POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 80 ITALY POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 81 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION) TABLE 82 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION) TABLE 83 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030 (USD MILLION) TABLE 84 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030 (USD MILLION) TABLE 85 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030 (USD MILLION) TABLE 86 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION) TABLE 87 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION) TABLE 88 BRAZIL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 89 BRAZIL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 90 ARGENTINA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 91 ARGENTINA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION) TABLE 92 COLUMBIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION) TABLE 93 COLUMBIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)

FIGURE 1 GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET, 2021–2030, (USD MILLION)
FIGURE 2 RESEARCH METHODOLOGY
FIGURE 3 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET, 2021–2030, (USD MILLION)
FIGURE 4 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET, 2021–2030, (USD MILLION)
FIGURE 5 MARKET OVERVIEW
FIGURE 6 SWOT ANALYSIS
FIGURE 7 MARKET SHARE ANALYSIS
FIGURE 8 SUPPLY CHAIN ANALYSIS
FIGURE 9 PORTER’S FIVE FORCES ANALYSIS
FIGURE 10 POINT-OF-CARE GLUCOSE TESTING TYPE ANALYSIS
FIGURE 11 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 12 POINT-OF-CARE GLUCOSE TESTING PRODUCT ANALYSIS
FIGURE 13 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET PRODUCT ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 14 POINT-OF-CARE GLUCOSE TESTING TECHNOLOGY ANALYSIS
FIGURE 15 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET TECHNOLOGY ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 16 POINT-OF-CARE GLUCOSE TESTING PRESCRIPTION ANALYSIS
FIGURE 17 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET PRESCRIPTION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 18 POINT-OF-CARE GLUCOSE TESTING END USE ANALYSIS
FIGURE 19 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 20 POINT-OF-CARE GLUCOSE TESTING APPLICATION ANALYSIS
FIGURE 21 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 22 GLOBAL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 23 MARKET OVERVIEW, REGIONAL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 24 MARKET SHARE BY COUNTRY
FIGURE 25 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 26 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 27 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 28 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 29 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 30 NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 31 U.S. POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 32 U.S. POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 33 CANADA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 34 CANADA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 35 MEXICO POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 36 MEXICO POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 37 MARKET SHARE BY COUNTRY
FIGURE 38 APAC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 39 APAC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 40 APAC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 41 APAC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 42 APAC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 43 APAC POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 44 CHINA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 45 CHINA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 46 JAPAN POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 47 JAPAN POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 48 KOREA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 49 KOREA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 50 INDIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 51 INDIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 52 SOUTHEAST ASIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 53 SOUTHEAST ASIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 54 MARKET SHARE BY COUNTRY
FIGURE 55 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 56 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 57 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 58 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 59 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 60 MIDDLE EAST AND AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 61 SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 62 SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 63 UAE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 64 UAE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 65 EGYPT POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 66 EGYPT POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 67 NIGERIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 68 NIGERIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 69 SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 70 SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 71 MARKET SHARE BY COUNTRY
FIGURE 72 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 73 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 74 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 75 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 76 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 77 EUROPE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 78 GERMANY POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 79 GERMANY POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 80 FRANCE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 81 FRANCE POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 82 UK POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 83 UK POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 84 RUSSIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 85 RUSSIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 86 ITALY POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 87 ITALY POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 88 MARKET SHARE BY COUNTRY
FIGURE 89 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 90 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRODUCT ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 91 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TECHNOLOGY ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 92 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE PRESCRIPTION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 93 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 94 LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 95 BRAZIL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 96 BRAZIL POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 97 ARGENTINA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 98 ARGENTINA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 99 COLUMBIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 100 COLUMBIA POINT-OF-CARE GLUCOSE TESTING CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 101 FINANCIAL OVERVIEW: